In Vivo Gene Editing Breakthrough: CRISPR Therapeutics Announces Exceptional Phase 1b Results for Single-Dose Cardiovascular Therapy
On February 19, 2026, CRISPR Therapeutics reported groundbreaking interim data from its ongoing Phase 1b clinical trial of CTX310, an investigational in vivo base editing therapy. The single intravenous infusion
By
Tung Nguyen
/
